Research Team Discovers New Immune “Checkpoint” Protein
A recent report in the journal Cell showed that a team led by Vanderbilt researchers has found a new “checkpoint” protein on immune system cells in active, malignant tumors. In mouse models, blocking this protein, along with using other treatments, has been an effective approach to treating cancerous cells. Checkpoint proteins are an important component of […]
Continue readingEstablishment of Immuno-oncology as a Cancer Therapy
Immuno-oncology is set to become one of the most vital cancer treatments, rising up into the realms surgery, chemotherapy, radiotherapy, and other targeted therapies. From their study, “Pharma Focus Visual Analysis of Immuno-Oncology Development and Opportunities”, Global Data was able to reach a conclusion and has analyzed more than 4,000 clinical trials of over 800 […]
Continue readingUsing PET Scans to Determine the Efficacy of PD-1 and PD-L1 Targeted Cancer Therapies
Summary According to a recent study that appeared in the March 2018 volume of The Journal of Nuclear Medicine, scientists at Bristol-Meyers Squibb (BMS) are developing a new way for physicians to determine how cancer patients might respond to PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) targeted treatments. Previously, the […]
Continue readingImmunotherapy Innovation Involving Checkpoint Inhibitors Gaining Momentum
A new innovation has shown great success in treating different kinds of tumors in mice that do not react to cancer immunotherapy medications, and they are called checkpoint inhibitors. Y-traps aim at the same proteins as existing checkpoint inhibitors: cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1)/PD-1 ligand (PD-L1). These proteins are known to assist […]
Continue reading